AstraZeneca Annual Report and Form 20-F Information 2011 Registered office and  corporate headquarters AstraZeneca PLC 2 Kingdom Street London W2 6BD UK Tel: +44 (0)20 7604 8000 Fax: +44 (0)20 7604 8151 Investor relations Email:  UK: as above Sweden:  Investor Relations AstraZeneca AB SE-151 85 Södertälje Sweden Tel: +46 (0)8 553 260 00 Fax: +46 (0)8 553 290 00 US: Investor Relations AstraZeneca Pharmaceuticals LP 1800 Concord Pike PO Box 15437 Wilmington DE 19850-5437 US Tel: +1 (302) 886 3000 Fax: +1 (302) 886 2972 Registrar Equiniti Limited  Aspect House Spencer Road Lancing West Sussex BN99 6DA UK Tel (freephone in the UK):  0800 389 1580 Tel (outside the UK):  +44 (0)121 415 7033 Swedish Central Securities  Depository Euroclear Sweden AB PO Box 191 SE-101 23 Stockholm Sweden Tel: +46 (0)8 402 9000 US Depositary JPMorgan Chase & Co PO Box 64504 St Paul MN 55164-0504 US Tel (toll free in the US):  888 697 8018 Tel (outside the US):  +1 (651) 453 2128 Email:  Contact information AstraZeneca Annual Report   and Form 20-F Information 201 1 This Annual Report is also available on our website,   astrazeneca.com/annualreport201 1 health    connectsusall Improving health is one of the toughest challenges facing the   world today. As a global biopharmaceutical company, AstraZeneca  has a key contribution to make by providing innovative medicines  for some of the world’s most serious diseases. We know that if we are to deliver medicines that people really need and value, we cannot   do it in isolation. We work closely with all our stakeholders to understand their needs and  challenges. We are committed to acting with integrity and high ethical standards in everything  we do and our goal is always to improve health for patients and bring benefit for our  stakeholders, our business and society. Important information for readers of this Annual Report Cautionary statement regarding forward-looking statements The purpose of this Annual Report is to provide information to the members of the  Company. The Company and its Directors, employees, agents and advisors do not  accept or assume responsibility to any other person to whom this Annual Report is  shown or into whose hands it may come and any such responsibility or liability is  expressly disclaimed. In order, among other things, to utilise the ‘safe harbour’  provisions of the US Private Securities Litigation Reform Act of 1995 and the UK  Companies Act 2006, we are providing the following cautionary statement: This  Annual Report contains certain forward-looking statements with respect to the  operations, performance and financial condition of the Group. Forward-looking  statements are statements relating to the future which are based on information  available at the time such statements are made, including information relating to risks  and uncertainties. Although we believe that the forward-looking statements in this  Annual Report are based on reasonable assumptions, the matters discussed in the  forward-looking statements may be influenced by factors that could cause actual  outcomes and results to be materially different from those expressed or implied by  these statements..